FEDI, SANDRA
 Distribuzione geografica
Continente #
NA - Nord America 4.913
EU - Europa 3.891
AS - Asia 406
AF - Africa 16
OC - Oceania 2
SA - Sud America 1
Totale 9.229
Nazione #
US - Stati Uniti d'America 4.901
PL - Polonia 1.980
IE - Irlanda 443
SE - Svezia 415
UA - Ucraina 343
IT - Italia 251
DE - Germania 216
HK - Hong Kong 198
FI - Finlandia 110
GB - Regno Unito 75
TR - Turchia 73
CN - Cina 44
JO - Giordania 33
VN - Vietnam 31
FR - Francia 30
SC - Seychelles 16
CH - Svizzera 13
CA - Canada 11
IN - India 11
JP - Giappone 7
SG - Singapore 6
AT - Austria 4
NL - Olanda 4
AU - Australia 2
BE - Belgio 2
RU - Federazione Russa 2
BR - Brasile 1
EE - Estonia 1
ES - Italia 1
HU - Ungheria 1
KR - Corea 1
MX - Messico 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 9.229
Città #
Warsaw 1.980
Fairfield 767
Jacksonville 540
Chandler 479
Dublin 443
Ashburn 346
Woodbridge 345
Seattle 341
Wilmington 292
Cambridge 276
Houston 268
Hong Kong 118
Princeton 109
Ann Arbor 101
Boardman 95
Boston 87
Altamura 75
Lawrence 61
Buffalo 45
Medford 39
San Diego 24
Dong Ket 22
Izmir 22
Frankfurt Am Main 20
Hillsboro 20
Milan 20
Auburn Hills 19
Beijing 19
Shanghai 19
Norwalk 18
Andover 14
New York 14
Falls Church 13
Phoenix 13
Bern 12
Florence 12
Los Angeles 12
Verona 12
West Jordan 12
Salerno 10
London 8
Chicago 6
Toronto 6
Fuzhou 5
Singapore 5
Hanover 4
Tappahannock 4
Vienna 4
Detroit 3
Laurel 3
Redmond 3
Atessa 2
Bremen 2
Brussels 2
Chiswick 2
Dearborn 2
Helsinki 2
Leicester 2
Munich 2
New Bedfont 2
Palermo 2
Philadelphia 2
Prato 2
Pune 2
Tokyo 2
Washington 2
Acton 1
Avezzano 1
Azcapotzalco 1
Bangkok 1
Brisbane 1
Budapest 1
Carate Brianza 1
Chiusdino 1
Colle Di Val D'elsa 1
Dallas 1
Düsseldorf 1
Edinburgh 1
Frankfurt am Main 1
Glasgow 1
Grevenbroich 1
Hanoi 1
Kunming 1
Lachine 1
Latina 1
Madrid 1
Manchester 1
Mcallen 1
Melbourne 1
Messina 1
Monte 1
Montichiari 1
Montreal 1
Montréal 1
Morrisville 1
Naaldwijk 1
Northampton 1
Old Bridge 1
Prad am Stilfser Joch 1
Radcliffe 1
Totale 7.249
Nome #
Protein Z gene polymorphisms (intron F 79G>A; -13 A>G) are not associated with acute coronary syndromes 244
Low protein Z levels in patients with peripheral arterial disease 234
A meta-analysis of potential risks of of low levels of protein Z for diseases related to vascular thrombosis 231
High lipoprotein (a) levels are associated with an increased risk of retinal vein occlusion 225
Protein Z is not synthesised by human umbilical vein endothelial cells 218
Fish intake and LPA 93C>T polymorphism: gene-environment interaction in modulating lipoprotein (a) concentrations 218
Modifications of protein Z and interleukin-6 during the acute phase of coronary artery disease 212
Homocysteine and tissue factor pathway inhibitor levels in patients with Fabry's disease 212
Hypercoagulability, high tissue factor and low tissue factor pathway inhibitor levels in severe ovarian hyperstimulation syndrome: possible association with clinical outcome. 210
Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. 205
Lower homocysteine levels in renal transplant recipients treated with everolimus: a possible link with a decreased cardiovascular risk? 199
Evaluation of traditional and emerging cardiovascular risk factors in patients with non-arteritic anterior ischemic optic neuroparty: a case-control study 195
Angiotensi-converting enzyme DD genotype, angiotensin type 1 receptor CC genotype, and hyperhomocysteinmeia increase first-trimester fetal-loss susceptibility 189
Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. 184
Protein Z: "Light and Shade" of a new thrombotic factor 179
D-Dimer in intra-uterine growth retardation and gestational hypertension 113
D-dimer concentrations during normal pregnancy, as measured by ELISA 107
ACE DD genotype: an independent predisposition factor to venous thromboembolism. 103
Protein Z plasma levels in different phases of activity of coronary atherosclerosis 100
Thrombophilias as risk factors for disorders of pregnancy and fetal damage 93
D-dimer plasma levels during normal pregnancy measured by specific ELISA 93
Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus 92
Activation of the immune system and coronary artery disease: the role of anti-endothelial cell antibodies. 92
EFFECT OF TOURNIQUET USE ON ACTIVATION OF COAGULATION IN TOTAL KNEE REPLACEMENT 91
Evaluation of clotting and fibrinolytic activation after protracted physical exercise 91
Atherosclerotic and thrombophilic risk factors in patients with ischemic central retinal vein occlusion 91
D-dimer increase after percutaneous transluminal angioplasty and clinical recurrence after primary revascularization in acute myocardial infarction? A pilot study 90
RISK FACTORS FOR CARDIOVASCULAR DISEASE IN RENAL TRANSPLANT RECIPIENTS: NEW INSIGHTS 89
Hyperhomocysteinemia in renal transplant patients as independent cause of endothelial damage and cardiovascular disease. 89
Blood clotting activation during normal pregnancy 89
Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies. 88
Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism 87
Low vitamin B6 and folic acid levels are associated with retinal vein occlusion independently of homocysteine levels. 86
A proinflammatory state is associated with hyperhomocysteinemia in the elderly 86
The influence of smoking on von Willebrand factor is already manifest in healthy adolescent females: the Floren-teen (Florence Teenager) Study. 85
Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients 85
Clottable to immunological fibrinogen ratio in plasma from control subjects and hyperfibrinogenemic patients 84
Effect of temperature and incubation time on D-dimer serum levels in healthy subjects. 84
Electrophysiologic procedures and activation of the hemostatic system 83
Platelet and blood clotting activation in patients with mitral valve prolapse 83
The role of cysteine and homocysteine in venous and arterial thrombotic disease. 82
Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. 82
Leisure-time but not occupational physical activity significantly affects cardiovascular risk factors in an adult population 82
FIBRINOLYTIC PARAMETERS IN YOUNG ADULTS: THE FLOREN-TEEN ( FLORENCE TEENAGER) STUDY 81
A hypercoagulable and hypofibrinolytic state is detectable by global methods in patients with retinal vein occlusion. 81
Antiphospholipid antibodies and pregnancy disorders in women with insulin dependent diabetes 80
Influence of endothelial nitric oxide synthase gene polymorphisms (G894T, 4a4b, T-786C) and hyperhomocysteinemia on the predisposition to acute coronary syndromes 79
Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. 78
Fibrinolysis alterations in infertile women during controlled ovarian stimulation: Influence of BMI and genetic components. 77
Is tissue factor pathway inhibitor a marker of procoagulable status in healthy infertile women undergoing ovarian stimulation for assisted reproduction? 77
TISSUE FACTOR AND HOMOCYSTEINE LEVELS IN ISCHEMIC HEART DISEASE ARE ASSOCIATED WITH ANGIOGRAPHICALLY DOCUMENTED CLINICAL RECURRENCES AFTER CORONARY ANGIOPLASTY 76
Protein Z levels and prognosis in patients with acute coronary syndromes 75
Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients 72
Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term low-molecular-weight heparin administration. 72
High prevalence of mild hyperhomocysteinemia in patients with abdominal aortic aneurysm 72
Relevance of post-methionine homocysteine and lipoprotein (a) in evaluating the cardiovascular risk in young CAD patients. 71
Homocysteine-lowering therapy and carotid intima-media thickness in renal transplant recipients. 71
Percutaneous transluminal coronary angioplasty procedure is associated to a decrease in transforming growth factor beta 1 levels 71
Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion 70
Thrombophilic risk factors in patients with severe carotid atherosclerosis 69
Thrombophilic risk factors in patients with central retinal vein occlusion. 69
TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit 69
Molecular mechanism underlying impaired platelet responsiveness in liver cirrhosis 69
Plasma and serum levels of D-dimer and their correlations with other hemostatic parameters in pregnancy. 68
Alterations of haemorheological parameters in patients with Peripheral Arterial Disease 66
Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. 66
Hyperhomocysteinemia and hypercoagulability in primary biliary cirrhosis. 65
Relatioship between the platelet aggregation of the newborn and mother 64
Low protein Z levels are independently associated with acute coronary syndromes 64
Evaluation of the prevalence of severe hyperhomocysteinemia in adult patients with thrombosis who underwent screening for thrombophilia 64
Hyperhomocysteinemia in patients with pulmonary embolism is associated with impaired plasma fibrinolytic capacity 62
Anticoagulant effect of dabigatran, rivaroxaban or apixaban treatment on different laboratory hemostasis tests in patients with atrial fibrillation 62
A mixture of bupivacaine and fentanyl in epidural block in orthopedic surgery: effects on blood coagulation and fibrinolysys 61
Hyperhomocysteinemia and vitamin B6 deficiency: new risk markers for nonvalvular atrial fibrillation? 61
Dietary habits, lifestyle and cardiovascular risk factors in a clinically healthy Italian population: the “Florence” diet is not Mediterranean 56
Reduced platelet thromboxane A2 production as a possible cause of defective platelet aggregation in cirrhosis. 55
Acute pyhase proteins in alcoholics with or without liver injury 55
Acquired activated protein C resistance in postmenopausal women is dependent on factor VIII:c levels. 54
Changes in lipid and hemostatic parameters induced by tibolone treatment 54
Activation of the coagulation system during electrophysiologic invasive study with and without ablation 54
Hemostatic disorders in 25 patients with limited and uncomplicated thyroid and breast cancer: prophylactic and therapeutic considerations 53
Antiphospholipid antibodies : a new risk factor for restenosis after percutaneous transluminal coronary angioplasty? 53
Evaluation of a new point-of-care celite-activated clotting time analyzer in different clinical settings. The i-STAT celite-activated clotting time test. 51
D-dimer plasma levels in pathological pregnancy: use of a rapid test (NycoCard). 50
Coparison of some serum copper parameters in treined runners and control subjects 47
Hyperhomocysteinemia in renal transplant patients: an independent factor of cardiovascular disease 47
Persistent generation of thrombin after coronary angioplasty 45
Changes in fibrinolysis after primary PTCA 45
Omocisteina e malattie cerebrovascolari 45
Protein Z levels, protein Z G79A polymorphism, and prothrombotic conditions 43
Nuovi fattori di rischio per la patologia carotidea 43
Substance P-induced fibrinolysis in teh forearm of healthy humans 42
High prevalence of anti-beta2 glycoprotein I antibodies in patients with ischemic heart disease 41
Procedure-dependence and tissue factor-indipendence of hypercoagulability during orthopaedic surgery 39
Hyperhomocysteinemia and abdominal aortic aneurysm 38
Iperomocisteinemia in pazienti con aneurisma dell’aorta addominale: nuovo fattore patogenetico? 38
Postprocedural PAI-activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective baloon PTCA 37
Accuracy of a Point-of-Care system for PT/INR test performed in the hospital anticoagulation clinic 36
COMPARISON OF THREE METHODS FOR TOTAL HOMOCYSTEINE PLASMA DETERMINATION 36
Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and in patients after percutaneous transluminal coronary angioplasty (PTCA) 35
Totale 9.049
Categoria #
all - tutte 22.229
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.229


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019622 0 0 0 0 0 0 0 0 0 0 338 284
2019/20202.254 158 228 70 224 233 290 206 310 193 108 198 36
2020/20211.387 104 102 123 167 39 180 55 153 82 201 42 139
2021/2022724 26 55 63 30 36 29 14 48 32 37 165 189
2022/20231.822 177 246 69 163 183 350 258 106 185 7 51 27
2023/2024551 35 73 117 30 32 87 26 134 2 15 0 0
Totale 9.292